Controlled study on Bupropion Sustained-Release Tablets and Paroxetine in the treatment of depression induced by Parkinson′s disease
LIAN Peng1 SUN Meng-meng1 FENG Lin1 FENG Xiao-li1 ZHANG Can-wen2
1.No.1 Department of Clinical Psychiatry,Tai′an Psychiatric Hospital,Shandong Province,Tai′an 271000,China;
2.Department of Neurology,Affiliated Hospital of Taishan Medical University,Shandong Province,Tai′an 271000,China
Abstract：Objective To compare the efficacy of Bupropion Sustained-Release Tablets and Paroxetine in improving depression and quality of life in the patients with Parkinson′s disease.Methods From February 2016 to September 2017,42 patients with Parkinson′s disease complicated with depression who were were admitted to the outpatient and inpatient in Tai′an Psychiatric Hospital were selected.The random number table was used to divide them into study group and control group,21 patients in each group.The study group was given Bupropion Sustained-Release Tablets for treatment,and the control group was given Paroxetine for treatment.The course of treatment was 6 weeks.The degree of depression changes was assessed by the Hamilton Depression Scale(HAMD).The third subscale of the comprehensive Parkinson′s disease rating Scale(UPDRS)was used to assess motor function.39-item Parkinson′s disease questionnaire(PDQ-39)scores were used to assess the changes in quality of life.Results Before treatment,the scores of HAMD,UPDRS,and PDQ-39 in the two groups of patients were compared,and the differences were not statistically significant(P＞0.05).After 2,4,and 6 weeks of treatment,the HAMD scores in both groups were significantly lower than those before treatment,and the differences were statistically significant(P＜0.01).There was no statistically significant difference in HAMD scores between the two groups(P＞0.05);the third subscale of UPDRS and PDQ-39 score in the study group at 2,4 and 6 weeks were significantly lower than those before treatment(P＜0.01).There was no statistically significant difference in the control group compared with that before treatment(P＞0.05).Conclusion Bupropion Sustained-Release Tablets can not only improve the depression of the patients with Parkinson′s disease,but also improve the motor symptoms and quality of life in the patients with Parkinson′s disease and depression,which is worthy of promotion.
廉鹏； 孙梦梦 ；冯琳 ；冯晓莉 ；张灿文. 安非他酮缓释片与帕罗西汀治疗帕金森病抑郁的对照研究[J]. 中国当代医药, 2018, 25(13): 147-150.
LIAN Peng；SUN Meng-meng；FENG Lin；FENG Xiao-li；ZHANG Can-wen. Controlled study on Bupropion Sustained-Release Tablets and Paroxetine in the treatment of depression induced by Parkinson′s disease. 中国当代医药, 2018, 25(13): 147-150.
Achey MA，Beck CA，Beran DB，et al.Virtual house calls for Parkinson disease（Connnect.Parkinson）：study protocol for a randomized，controlled[J].Trials，2014，15（1）：465-467.
Tsang KL，Chi I，Ho SL，et al.Translation and validation of the standard Chinese version of PDQ-39：a quality-of-life measure for patients with Parkinson′s disease[J].Mov Disord，2002，17（5）：1036-1040.
[13]
Connolly BS，Lang AE.Pharmacological treatment of Parkinson disease：a review[J].JAMA，2014，311（16）：1670-1683.
京公网安备 11010502046607号